|
1
|
Boily G, Ouellet S, Langlois S, Larivière
M, Drouin R and Sinnett D: In vivo footprinting analysis of the
Glypican 3 (GPC3) promoter region in neuroblastoma cells. Biochim
Biophys Acta. 1769:182–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Filmus J and Selleck SB: Glypicans:
Proteoglycans with a surprise. J Clin Invest. 108:497–501. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Filmus J, Capurro M and Rast J: Glypicans.
GENOME BIOL 2008 2008-01-20. 9:224
|
|
4
|
Capurro MI, Xu P, Shi W, Li F, Jia A and
Filmus J: Glypican-3 inhibits Hedgehog signaling during development
by competing with patched for Hedgehog binding. Dev Cell.
14:700–711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filmus J and Capurro M: The role of
glypican-3 in the regulation of body size and cancer. Cell Cycle.
7:2787–2790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song HH and Filmus J: The role of
glypicans in mammalian development. Biochim Biophys Acta.
1573:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pilia G, Hughes-Benzie RM, MacKenzie A,
Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A and
Schlessinger D: Mutations in GPC3, a glypican gene, cause the
Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 12:241–247.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Shuman C, Fei YL, Cutiongco E,
Bender HA, Stevens C, Wilkins-Haug L, Day-Salvatore D, Yong SL,
Geraghty MT, et al: GPC3 mutation analysis in a spectrum of
patients with overgrowth expands the phenotype of
Simpson-Golabi-Behmel syndrome. Am J Med Genet. 102:161–168. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakatsura T, Kageshita T, Ito S, Wakamatsu
K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification
of glypican-3 as a novel tumor marker for melanoma. Clin Cancer
Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maeda D, Ota S, Takazawa Y, Aburatani H,
Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3
expression in clear cell adenocarcinoma of the ovary. Mod Pathol.
22:824–832. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zynger DL, Dimov ND, Luan C, Teh BT and
Yang XJ: Glypican 3: A novel marker in testicular germ cell tumors.
Am J Surg Pathol. 30:1570–1575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmilovitz-Weiss H, Tobar A, Halpern M,
Levy I, Shabtai E and Ben-Ari Z: Tissue expression of squamous
cellular carcinoma antigen and Ki67 in hepatocellular
carcinoma-correlation with prognosis: a historical prospective
study. Diagn Pathol. 6:1212001. View Article : Google Scholar
|
|
13
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu
GT, Wang XH, Gao WH, Sun YT, Feng XL, et al: Tight association of
hepatocellular carcinoma with HBV infection in North China.
Hepatobiliary Pancreat Dis Int. 4:46–49. 2005.PubMed/NCBI
|
|
15
|
Wang HL, Anatelli F, Zhai QJ, Adley B,
Chuang ST and Yang XJ: Glypican-3 as a useful diagnostic marker
that distinguishes hepatocellular carcinoma from benign
hepatocellular mass lesions. Arch Pathol Lab Med. 132:1723–1728.
2008.PubMed/NCBI
|
|
16
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system.
4th edition. Int Agen Res Cancer Lyon. 1089:2010.
|
|
17
|
Shirakawa H, Kuronuma T, Nishimura Y,
Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M,
Kobayashi N, et al: Glypican-3 is a useful diagnostic marker for a
component of hepatocellular carcinoma in human liver cancer. Int J
Oncol. 34:649–656. 2009.PubMed/NCBI
|
|
18
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1525. 2009. View Article : Google Scholar
|
|
19
|
Wang SS, Chen YH, Ning C, Wang LJ, Chen
DX, Weng HL, Dooley S and Ding HG: Hydrogen sulfide promotes
autophagy of hepatocellular carcinoma cells through the
PI3K/Akt/mTOR signaling pathway. Cell Death Dis. 8:e26882017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki
K, Uchida H, Shibata K, Ohta M and Kitano S: Short- and long-term
outcomes after hepatic resection for hepatocellular carcinoma with
concomitant esophageal varices in patients with cirrhosis. Ann Surg
Oncol. 15:1670–1676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan
YF, Li N and Ding HG: Diagnostic value of glypican-3 in serum and
liver for primary hepatocellular carcinoma. World J Gastroenterol.
16:4410–4415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iglesias BV, Centeno G, Pascuccelli H,
Ward F, Peters MG, Filmus J, Puricelli L and de Kier Joffé EB:
Expression pattern of glypican-3 (GPC3) during human embryonic and
fetal development. Histol Histopathol. 23:1333–1340.
2008.PubMed/NCBI
|
|
24
|
Jian R, Zheng DY and Luo RC: The
expression of GPC3 in human malignant cancers and its potential
clinical application. Tumor. 31:863–866. 2011.
|
|
25
|
Suzuki M, Sugimoto K, Tanaka J, Tameda M,
Inagaki Y, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, et
al: Up-regulation of glypican-3 in human hepatocellular carcinoma.
Anticancer Res. 30:5055–5061. 2010.PubMed/NCBI
|
|
26
|
Lin Q, Xiong LW, Pan XF, Gen JF, Bao GL,
Sha HF, Feng JX, Ji CY and Chen M: Expression of GPC3 protein and
its significance in lung squamous cell carcinoma. Med Oncol.
29:663–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
An SJ, Huang YS, Chen ZH, Su J, Yang Y,
Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN, et al: Posttreatment
plasma VEGF levels may be associated with the overall survival of
patients with advanced non-small cell lung cancer treated with
bevacizumab plus chemotherapy. Med Oncol. 29:627–632. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mounajjed T, Zhang L and Wu TT: Glypican-3
expression in gastrointestinal and pancreatic epithelial neoplasms.
Hum Pathol. 44:542–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Valsechi MC, Oliveira AB, Conceição AL,
Stuqui B, Candido NM, Provazzi PJ, de Araújo LF, Silva WA Jr,
Calmon Mde F and Rahal P: GPC3 reduces cell proliferation in renal
carcinoma cell lines. BMC Cancer. 14:6312014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stigliano I, Puricelli L, Filmus J,
Sogayar MC, Bal de Kier Joffé E and Peters MG: Glypican-3 regulates
migration, adhesion and actin cytoskeleton organization in mammary
tumor cells through Wnt signaling modulation. Breast Cancer Res
Treat. 114:251–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao W and Ho M: The role of glypican-3 in
regulating Wnt in hepatocellular carcinomas. Cancer Rep. 1:14–19.
2011.PubMed/NCBI
|
|
32
|
Pan Z, Chen C, Long H, Lei C, Tang G, Li
L, Feng J and Chen F: Overexpression of GPC3 inhibits
hepatocellular carcinoma cell proliferation and invasion through
induction of apoptosis. Mol Med Rep. 7:969–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sakurai M, Shibata K, Umezu T, Kajiyama H,
Yamamoto E, Ino K, Nawa A and Kikkawa F: Growth-suppressing
function of glypican-3 (GPC3) via insulin like growth factor II
(IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Gynecol Oncol. 119:332–336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY,
Liu ZK, Qiu ZD, Lin MZ, Chen NP and Chen M: Knockdown of GPC3
inhibits the proliferation of Huh7 hepatocellular carcinoma cells
through down-regulation of YAP. J Cell Biochem. 114:625–631. 2013.
View Article : Google Scholar : PubMed/NCBI
|
